Abstract: A converged system includes a computing node and a storage node. The computing node is connected to the storage node through a network to build a storage-computing decoupled architecture. A storage medium of the computing node and a storage medium of the storage node form a global memory pool through unified addressing, namely, a global storage medium shared by the computing node and the storage node. When a read/write operation is performed in the system, processing request data is obtained, and a memory operation of the processing request data is performed on the global memory pool based on a memory operation instruction.

Abstract: A mineral water comprising a composition of a blend of minerals and trace rare earth elements is provided, the rare earth elements in the composition comprise Scandium, Yttrium, Lanthanum, Cerium, Praseodymium, Neodymium, Samarium, Europium, Gadolinium, Terbium, Dysprosium, Holmium, Erbium, Thulium, Ytterbium, Lutetium. The water is conducive to good health and can relieve the symptoms of some chronic diseases.

Abstract: The disclosure is directed to compounds of Formula I: processes for their preparation, treatment of central nervous system (CNS) disorders and methods for the modulation of 5HT6 activity.

Abstract: The present invention provides a compound of formula I and the use thereof in the therapeutic treatment of disorders related to or affected by the 5-HT6 receptor.

Abstract: The present invention provides a compound of formula I and the use thereof in the therapeutic treatment of disorders related to or affected by the 5-HT6 receptor.

Abstract: The present invention provides a compound of formula I and the use thereof in the therapeutic treatment of disorders related to or affected by the 5-HT6 receptor.

Abstract: The present invention provides a compound of formula I and the use thereof in the therapeutic treatment of disorders related to or affected by the 5-HT6 receptor

Abstract: A compound of formula (I) and pharmaceutically acceptable salts, solvates and hydrolysable esters thereof wherein: X1 is O or S; X2 is O or S; n is 1–3, One of Y and Z is N, and the other is O; R1 and R2 are independently halogen, H, CH3, OCH3 or C1-3 alkyl; Each R3 independently is halogen, CF3, C1-6 straight or branched alkyl; R4 and R5 are independently H or C1-3 alkyl. y is 0, 1, 2, 3, 4 or 5.

Abstract: Compounds of formula (1) or a pharmaceutically acceptable salt, solvate, acid isostere, or hydrolyzable ester thereof, are disclosed. Methods of making and using the compounds are also disclosed. In particular methods for treating diseases or conditions associated with one or more of human PPAR alpha, gamma, or delta (“hPPARs”) comprising administration of a therapeutically effective amount of a compound of formula (1), are disclosed.

Abstract: The present invention provides a compound of formula I and the use thereof in the therapeutic treatment of disorders related to or affected by the 5-HT6 receptor.

Abstract: The present invention provides non-peptide cathepsin D binding compounds and methods for using such compounds in the detection, labelling and inhibition of cathepsin D.